Genertec Universal Medical Group (2666) Fundamentals 2026 — P/E 3.6x, Revenue Analysis | SniperIQ
Genertec Universal Medical Group (2666) is a CN-listed Financial Services company in Financial - Credit Services with a market capitalization of HK$9.6B, trading at HK$4.77 on the HKSE. This SniperIQ fundamentals page covers Genertec Universal Medical Group's valuation (P/E 3.6x, P/B 0.4x), profitability (net margin 15.2%), revenue (¥14.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Genertec Universal Medical Group's market cap?
Genertec Universal Medical Group (2666) has a market capitalization of approximately HK$9.6B, trading at HK$4.77 on the HKSE. Market cap moves with the live share price.
What is Genertec Universal Medical Group's P/E ratio?
Genertec Universal Medical Group's trailing twelve-month P/E ratio is 3.6x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Financial Services sector peers rather than read in isolation.
How profitable is Genertec Universal Medical Group?
Genertec Universal Medical Group runs a net profit margin of 15.2%, a gross margin of 100.0%, and an operating margin of 58.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Genertec Universal Medical Group generate?
Genertec Universal Medical Group reported revenue of ¥14.5B for fiscal year 2025, with net income of ¥2.2B and earnings per share (EPS) of 1.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Genertec Universal Medical Group pay a dividend?
Genertec Universal Medical Group offers a trailing dividend yield of about 7.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Genertec Universal Medical Group financially healthy?
Genertec Universal Medical Group carries a debt-to-equity ratio of 2.60x and a current ratio of 3.64x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Genertec Universal Medical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Genertec Universal Medical Group (2666) the key facts are: market cap HK$9.6B, P/E 3.6x, revenue ¥14.5B, 52-week range 4.32-6.71. Weigh valuation, profitability, growth, and balance-sheet strength against Financial Services peers and form your own view.
Track Genertec Universal Medical Group's full fundamentals live
Get Genertec Universal Medical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.